M&A DealNews: DZ BANK advises shareholders of CNP Group

DZ BANK Corporate Finance advised the CNP Group on the sale of 100% of its shares to financial investor capiton, thereby facilitating a succession arrangement for the two shareholders. The CNP Group, which in Germany primarily operates as MIP Pharma, is a pan-European generics manufacturer with a strong presence in Eastern Europe and a broad registration portfolio with a focus on antibiotics, particularly in the field of clindamycins and cephalosporins. The CNP Group has production sites in St. Ingbert-Rohrbach and Homburg and currently employs around 250 people. capiton will make extensive investments at both production sites. The transaction was initiated by Bank 1 Saar.


On the DZ BANK side, Dr. Wolfgang Wybranietz, Alex Brozmann, Sebastian Braun, and Nico Bonaldo were responsible for the transaction.

My biggest thanks go to DZ BANK for their constant support over the past months and the highly professional advice during the sales process. DZ BANK's solution-oriented advice on various complex issues in a market environment influenced by COVID-19 was certainly the key to the successful completion of the transaction.

Client Ursula Seidel from the CNP Group on the transaction.

Alex Brozmann, DZ BANK

"Thanks to our proximity to the customer and our particular expertise in the pharmaceutical industry, we were able to achieve a very good overall result for the shareholders of the CNP Group despite difficult market conditions."

Dr. Wolfgang Wybranietz, DZ BANK

"The main task in the succession planning for shareholders of the CNP Group was to find a suitable buyer who would continue the life's work and plan extensive investments in the production facilities. The travel restrictions due to Corona were challenging. Thanks to the high professionalism of all parties involved, we were able to successfully conclude the transaction."

Further transactions